scholarly journals Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis

2017 ◽  
Vol 8 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Tomoaki Higashiyama ◽  
Sanae Muraki ◽  
Masahito Ohji
Keyword(s):  
Birth Weight ◽  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Gold Standard ◽  
Standard Treatment ◽  
Intravitreal Bevacizumab ◽  
Male Infant ◽  
Significant Benefit ◽  
Tunica Vasculosa Lentis

Background: Laser therapy has been the gold standard treatment for retinopathy of prematurity (ROP), while intravitreal bevacizumab (IVB) is reported to be of significant benefit for zone I ROP. A problem with laser therapy is that it is difficult to administer in ROP patients with severely dilated tunica vasculosa lentis and poor mydriasis. However, although IVB treatment has been performed in such severe ROP cases, only 1 report has discussed its usefulness. Case 1: A male infant was born with a birth weight of 382 g at 23 weeks’ gestation. As visualization was poor and laser therapy could not be performed due to dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Case 2: A male infant was born with a birth weight of 698 g at 25 weeks’ gestation. As laser therapy could not be performed due to severely dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Conclusions: IVB is potentially more useful than laser therapy for the treatment of severe ROP with dilated tunica vasculosa lentis and poor mydriasis.

scholarly journals Intravitreal Bevacizumab to Treat Retinopathy of Prematurity in 865 Eyes: a Study to Determine Predictors of Primary Treatment Failure and Recurrence

2021 ◽  
Author(s):  
Kaveh Fadakar ◽  
Mohammadreza Mehrabi Bahar ◽  
Hamid Riazi-Esfahani ◽  
Afsaneh Azarkish ◽  
Afsar Dastjani Farahani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Birth Weight ◽  
Treatment Failure ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Primary Treatment ◽  
Anti Vegf ◽  
History Of ◽  
Mean Time

Abstract Purpose: This study aimed To evaluate the rate and risk factors for primary failure and recurrence after intravitreal anti-VEGF injection in retinopathy of prematurity (ROP).Methods: This retrospective study was performed on 865 eyes from 441 patients with retinopathy of prematurity receiving intravitreal Bevacizumab from 2012 to 2019. Medical records of patients were evaluated.Results: Mean gestational age (GA) and birth weight of patients were 28±2 weeks and 1121±312 g, respectively. Thirty-five eyes (4.04%) had a primary failure, including 18 eyes from 187 eyes in zone 1 (9.6%) and 17 eyes from 678 eyes in zone 2 (2.5%). The mean time of retreatment was 16.64±13.68 days in eyes without regression ROP. The remaining 830 eyes (95.95%) were included in recurrence analysis. The recurrence occurred in 33 eyes (3.97 %) of them in 20 patients, with the meantime of 77.52 days after the first treatment (IVB). Presence of plus disease, history of oxygen therapy or phototherapy, and GA less than 32 were associated with significantly increased prevalence of treatment failure. The risk factor predicting recurrence are lower birth weight, zone 1 pretreatment, history of intubation, anemia, and sepsis.Conclusion: Intravitreal anti-VEGF is a successful treatment for ROP with a low rate of primary failure and recurrence. Attention to risk factors accompanied by special care to patterns of treatment failure and recurrence helps to achieve early detection of treatment failure and vigilant follow up for recurrence.

scholarly journals Refractive Outcomes of Patients Treated for Retinopathy of Prematurity

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Ayesha Khan ◽  
Kathryn Haider
Keyword(s):  
Laser Therapy ◽  
Refractive Error ◽  
Retinopathy Of Prematurity ◽  
High Myopia ◽  
Intravitreal Bevacizumab ◽  
Treatment Groups ◽  
Patient Demographics ◽  
Refractive Outcomes ◽  
Eye Exams ◽  
Lost To Follow Up

Background:  Retinopathy of prematurity (ROP) is a disease where the blood vessels in the eye fail to develop appropriately in infants born prematurely. Two effective treatments for ROP include laser photocoagulation therapy and intravitreal bevacizumab (IVB). Laser therapy has been linked to causing high myopia in children post-treatment. We hypothesize that patients treated with IVB alone or in combination with laser will have less myopia development than patients treated with laser therapy alone.  Methods:  Patient demographics, treatment details, refractive data at 6-9 months and 3-4 years, the occurrence of strabismus at 3 years, and the most recent vision data were collected from 133 ROP patients. Patients not treated at IU health and those lost to follow-up, or deceased before both eye exams, were excluded from the study. Quantitative analysis was used to compare the refractive error, strabismus, and vision outcomes between the three treatment groups. A linear regression model was used to analyze the relationship between the number of laser spots applied and refractive error.  Results:  Refractive outcomes at 6-9 months and 3-4 years, occurrence of strabismus, and vision outcomes were statistically similar between the three treatment groups. However, the laser group had the most occurrences of high myopia. We also observed a 0.002 unit decrease in refractive error, reported at 6–9-months, with each laser spot applied (p<0.001). This may be due to the influence of outliers because no significant relationship was seen at the 3–4 year exam.  Conclusion and Potential Impact:  There was no difference in outcomes among patients treated with IVB, laser, or a combination of both, with the exception of more myopic outliers in the laser-only group. We can therefore assume that ROP patients who have received one of these three treatments had developed differences in myopia independent of treatment modality. 

scholarly journals Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

2016 ◽  
Vol 46 ◽  
pp. 764-768
Author(s):  
Ahmet Murad HONDUR ◽  
Mehmet Özgür ÇUBUK ◽  
Zühal ÖZEN TUNAY ◽  
Hatice Tuba ATALAY ◽  
Özdemir ÖZDEMİR ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab

Management of aggressive posterior retinopathy of prematurity in oculocutaneous albinism

2021 ◽  
Vol 14 (2) ◽  
pp. e238490
Author(s):  
Bhavik Panchal ◽  
Megha Gulati
Keyword(s):  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Male Infant ◽  
Oculocutaneous Albinism ◽  
Complete Regression ◽  
Vascular Endothelial ◽  
Postmenstrual Age ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

A male infant, born preterm at 32 weeks of gestation, was referred at 36-week postmenstrual age for retinopathy of prematurity (ROP) screening. He had nystagmus, generalised hypopigmentation of skin, hair and eyes with preaxial polydactyly. The fundus was depigmented with prominently visible choroidal vessels. The retinal vessels were dilated, tortuous at zone 1. There was presence of arcading, shunting of vessels with presence of vitreous haemorrhage in the left eye. A diagnosis of aggressive posterior retinopathy of prematurity (APROP) in association with oculocutaneous albinism (OCA) was made.Half-dose intravitreal bevacizumab was used to treat the vascular condition. After 2 weeks, there was complete regression of APROP with a completely mature retina observed at 4 months post-treatment. Herein, we describe the role of red-free light for screening ROP in infants with OCA; challenges in the management of ROP with laser photocoagulation compared with intravitreal anti-vascular endothelial growth factor therapy.

Sign in / Sign up

Export Citation Format

Share Document